VSVitalii O. Sinenko

Vitalii O. Sinenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vitalii O. Sinenko has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design, synthesis, structural diversity, ADMET profiling and DFT calculations of 1,2,4-oxadiazole-1,3-oxazole hybrids

    by Yelyzaveta Yu. Rybina, Ivan V. Semenyuta, Nataliya V. Obernikhina, Vitalii O. Sinenko

    To obtain new bioactive nitrogen-containing heterocycles, hybrid molecules incorporating two heterocyclic rings as potential dual binding sites for biomolecules were synthesized in this study. The resulting compounds combine 1,2,4-oxadiazole and 1,3-oxazole fragments within a single molecular framework. The starting materials for the synthesis of these heterocycles were amino-substituted 1,2,4-oxadiazole derivatives prepared from amidoximes and Boc-protected amino acids. Their reaction with enamides led to heterocyclization, affording the target products containing both 1,2,4-oxadiazole and 1,3-oxazole moieties. Using the proposed synthetic approach, 16 new compounds containing two heterocyclic rings linked by either acyclic or cyclic linkers were obtained. The structures of the synthesized compounds were reliably confirmed by elemental analysis and spectroscopic methods, including ¹H and ¹³C NMR spectroscopy, IR spectroscopy, and mass spectrometry. In addition, ADMET studies were performed to predict the drug-likeness of the synthesized compounds, and quantum-chemical calculations were carried out for model molecules. The proposed synthetic approach demonstrates versatility and enables the preparation of a large library of potentially bioactive 1,2,4-oxadiazole–1,3-oxazole hybrid molecules, which is useful for further investigation of diverse biological activities.

  • Open Access

    Design, Synthesis, and Antitumor Potential of New Thiazolecontained 5-Fluoro-2-Oxindole Derivatives as Sunitinib Analogues

    by Ivan Semenyuta, Oleksandr Los, Vitalii Sinenko, Victor Zhirnov, Lyudmyla Potikha, Oleksandr Kobzar, Volodymyr Brovarets

    Background: Indole is considered the most promising scaffold for anticancer drug design due to its high bioavailability, unique chemical properties, and broad spectrum of pharmacological action. Objective: Twelve novel thiazole-containing the 5-fluoro-1,3-dihydro-2H-indol-2-one derivatives as sunitinib analogs were designed and synthesized, and their anticancer activity was evaluated against the NCI-60 cancer cell lines. Methods: The thiazole-contained 5-fluoro-1,3-dihydro-2H-indol-2-one derivatives were synthesized using Knoevenagel condensation of 1,3-thiazole-5-carboxylic acid 1. Their anticancer activities were evaluated by NCI-60 one-dose screen assay. The molecular docking studies were performed using AutoDock tools and the AutoDock Vina programs. The ADMETlab 2.0 web server predicted the physicochemical properties of compounds. Results: Among the synthesized new 5-fluoro-2-oxindole derivatives, compound 3g demonstrated high antitumor activity (GI>70%) against eight types of cancer: leukemia, breast cancer, ovarian cancer, lung cancer, melanoma, CNS cancer, renal cancer, and colon cancer. The most activity was observed against breast cancer (T-47D, GI=96.17%), lung cancer (HOP-92, GI=95.95%), ovarian cancer (NCI/ADR-RES, GI=95.13%), and CNS cancer (SNB-75, GI=89.91%). The molecular docking results of compound 3g demonstrated the possibility of inhibiting VEGF2 receptors as his potential anticancer mechanism. The physicochemical properties predicted for compounds 3f and 3g showed positive results. Conclusion: Compound 3g demonstrated high in vitro NCI-60 anticancer activity against nine cancer types and showed cell growth inhibition against leukemia, CNS, and breast cancer at 6 - 31% higher than Sunitinib, and may represent the basis for further modification of the thiazole-containing analogs of the anticancer drug Sunitinib. Conclusion: Compound 3g demonstrated high in vitro NCI-60 anticancer activity against nine cancer types and showed cell growth inhibition against leukemia, CNS, and breast cancer at 6 - 31% higher than Sunitinib, and may represent the basis for further modification of the thiazole-containing analogs of the anticancer drug Sunitinib.